RNASEH1 and cancer: Together with our findings, these data suggest that particular sets of cancer cells, such as those carrying active ALT pathway, may be preferentially sensitive to DNA/RNA hybrid depletion and may be suitable targets for TAV/RNase H1 overexpression-based gene therapy.